Evidence map›Paper›PMID 28583578›Full record

ArticleThe Lancet. Infectious diseases2017

Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series.

Xiling Wang, Hui Jiang, Peng Wu, Timothy M Uyeki, Luzhao Feng, Shengjie Lai, Lili Wang, Xiang Huo, Ke Xu, Enfu Chen and 26 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in The Lancet. Infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03394209 (An Adaptive Study of the Pharmacokinetics of Favipiravir in Patients With Severe), which is not on this map. Cited by 165 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed, 4 pooled it
29.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03394209 phase2completednot on this mapstarted 2018, after this paper: background citation

An Adaptive Study of the Pharmacokinetics of Favipiravir in Patients With Severe

TypeinterventionalSponsorCapital Medical UniversityRan2018 to 2019Enrolled34ConditionsInfluenza, Human, Critical Illness, InfluenzaArmsFavipiravir, Oseltamivir 75Mg Capsule
3 · Its place in the literature

Who cites it

165 citing papers in PubMed, 4 syntheses or guidelines pooled it, 278 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors at 17 institutions in 5 countries.

Xiling WangSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
Hui JiangKey Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.
Peng WuWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Timothy M UyekiInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Luzhao FengKey Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.
Shengjie LaiKey Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.
Lili WangInstitute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.
Xiang HuoJiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Ke XuJiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Enfu ChenZhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Xiaoxiao WangZhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Jianfeng HeGuangdong Provincial Center for Disease Control and Prevention, Guangzhou, China.
Min KangGuangdong Provincial Center for Disease Control and Prevention, Guangzhou, China.
Renli ZhangShenzhen Center for Disease Control and Prevention, Shenzhen, China.
Jin ZhangAnhui Provincial Center for Disease Control and Prevention, Hefei, China.
Jiabing WuAnhui Provincial Center for Disease Control and Prevention, Hefei, China.
Shixiong HuHunan Provincial Center for Disease Control and Prevention, Changsha, China.
Hengjiao ZhangHunan Provincial Center for Disease Control and Prevention, Changsha, China.
Xiaoqing LiuJiangxi Provincial Center for Disease Control and Prevention, Nanchang, China.
Weijie FuJiangxi Provincial Center for Disease Control and Prevention, Nanchang, China.
Jianming OuFujian Provincial Center for Disease Control and Prevention, Fuzhou, China.
Shenggen WuFujian Provincial Center for Disease Control and Prevention, Fuzhou, China.
Ying QinKey Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.
Zhijie ZhangSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
Yujing ShiKey Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.
Juanjuan ZhangSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
Jean ArtoisSpatial Epidemiology Lab. (SpELL), 'Université Libre de Bruxelles', Brussels, Belgium.
Vicky J FangWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Huachen ZhuWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Centre of Influenza Research and State Key Laboratory of Emerging Infectious Diseases, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China; State Key Laboratory of Emerging Infectious Diseases (The University of Hong Kong-Shenzhen Branch), Shenzhen Third People's Hospital, Shenzhen, China; Shantou University-The University of Hong Kong Joint Institute of Virology, Shantou University, Shantou, China.
Yi GuanWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Centre of Influenza Research and State Key Laboratory of Emerging Infectious Diseases, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China; State Key Laboratory of Emerging Infectious Diseases (The University of Hong Kong-Shenzhen Branch), Shenzhen Third People's Hospital, Shenzhen, China; Shantou University-The University of Hong Kong Joint Institute of Virology, Shantou University, Shantou, China.
Marius GilbertSpatial Epidemiology Lab. (SpELL), 'Université Libre de Bruxelles', Brussels, Belgium; Fonds National de la Recherche Scientifique, Brussels, Belgium.
Peter W HorbyCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Gabriel M LeungWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
George F GaoChinese Center for Disease Control and Prevention, Beijing, China; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Benjamin J CowlingWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Hongjie YuSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China. Electronic address: cfetpyhj@vip.sina.com.
Chinese Center For Disease Control and Prevention · CNUniversity of Hong Kong · HKFudan University · CNAnhui Provincial Center for Disease Control and Prevention · CNGansu Provincial Center for Disease Control and Prevention · CNGuangdong Provincial Center for Disease Control and Prevention · CNHunan Provincial Center for Disease Control and Prevention · CNJiangsu Provincial Center for Disease Control and Prevention · CNNanchang Center for Disease Control and Prevention · CNChinese Academy of Sciences · CNFund for Scientific Research · BENational Center for Immunization and Respiratory Diseases · USShenzhen Center for Disease Control and Prevention · CNShenzhen Third People’s Hospital · CNUniversité Libre de Bruxelles · BEUniversity of Oxford · GBZhejiang Center for Disease Control and Prevention · CN

Funding

Understanding and controlling antibiotic resistanceU54GM088558 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI LIPSITCH, MARC · 2009 to 2018
$26.4M
Virology &ImmunologyU19AI051915 · NIAID · NATIONAL CENTER FOR AIDS/STD CONTROL AND PREVENTION · PI YU, HONGJIE · 2002 to 2009
$21.6M
Transmission dynamics and spillover of avian influenza under changing agriculturaR01AI101028 · NIAID · UNIVERSITY OF OKLAHOMA · PI XIAO, XIANGMING · 2013 to 2016
$1.9M
NIAID NIH HHS R01 AI101028NIAID NIH HHS U19 AI051915NIGMS NIH HHS U54 GM088558
6 · The paper itself

Abstract

backgroundThe avian influenza A H7N9 virus has caused infections in human beings in China since 2013. A large epidemic in 2016-17 prompted concerns that the epidemiology of the virus might have changed, increasing the threat of a pandemic. We aimed to describe the epidemiological characteristics, clinical severity, and time-to-event distributions of patients infected with A H7N9 in the 2016-17 epidemic compared with previous epidemics.

methodsIn this epidemiological study, we obtained information about all laboratory-confirmed human cases of A H7N9 virus infection reported in mainland China as of Feb 23, 2017, from an integrated electronic database managed by the China Center for Disease Control and Prevention (CDC) and provincial CDCs. Every identified human case of A H7N9 virus infection was required to be reported to China CDC within 24 h via a national surveillance system for notifiable infectious diseases. We described the epidemiological characteristics across epidemics, and estimated the risk of death, mechanical ventilation, and admission to the intensive care unit for patients admitted to hospital for routine clinical practice rather than for isolation purpose. We estimated the incubation periods, and time delays from illness onset to hospital admission, illness onset to initiation of antiviral treatment, and hospital admission to death or discharge using survival analysis techniques.

findingsBetween Feb 19, 2013, and Feb 23, 2017, 1220 laboratory-confirmed human infections with A H7N9 virus were reported in mainland China, with 134 cases reported in the spring of 2013, 306 in 2013-14, 219 in 2014-15, 114 in 2015-16, and 447 in 2016-17. The 2016-17 A H7N9 epidemic began earlier, spread to more districts and counties in affected provinces, and had more confirmed cases than previous epidemics. The proportion of cases in middle-aged adults increased steadily from 41% (55 of 134) to 57% (254 of 447) from the first epidemic to the 2016-17 epidemic. Proportions of cases in semi-urban and rural residents in the 2015-16 and 2016-17 epidemics (63% [72 of 114] and 61% [274 of 447], respectively) were higher than those in the first three epidemics (39% [52 of 134], 55% [169 of 306], and 56% [122 of 219], respectively). The clinical severity of individuals admitted to hospital in the 2016-17 epidemic was similar to that in the previous epidemics.

interpretationAge distribution and case sources have changed gradually across epidemics since 2013, while clinical severity has not changed substantially. Continued vigilance and sustained intensive control efforts are needed to minimise the risk of human infection with A H7N9 virus.

fundingThe National Science Fund for Distinguished Young Scholars.

Indexed as

EpidemicsAdolescentAdultAgedAged, 80 and overAge DistributionAnimalsAntiviral AgentsChildChild, PreschoolChinaClinical Laboratory TechniquesDisease NotificationEpidemiologic StudiesFemaleHospitalizationAntiviral Agents

Identifiers

PMID28583578
PMCPMC5988584
OpenAlexW2621065682

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.